Coherus BioSciences (CHRS) Conference Call Summary Company Overview - **Company**: Coherus BioSciences - **Event**: Jefferies Global Healthcare Conference - **Date**: June 04, 2025 Key Industry Insights - **Focus Areas**: Coherus Oncology is concentrating on three main areas: - Lactorsi (proprietary PD-1 asset) for nasopharyngeal cancer - CHS-114 (anti-CCR8 cytolytic antibody) - Casdozo ketog (IL-27 antagonist) [4][6][40] Core Product Highlights - **Lactorsi**: - Launched in 2024, it is the only preferred treatment for both first-line and follow-on lines in nasopharyngeal cancer - Expected revenue of $40 to $50 million in 2025 [12][40] - Targets a market of approximately $150 to $200 million annually [11] - Demonstrated a 15% increase in overall demand from the previous quarter [12] - **CHS-114**: - Targets T regulatory cells, aiming to selectively deplete them in tumors to enhance immune response - High expression of CCR8 in various solid tumors, including head and neck, gastric, and colorectal cancers [18][23] - Anticipated data readouts in the first half of 2026 [6][8] - **Casdozo ketog**: - First-in-class IL-27 antagonist showing promise in liver cancer with a 38% overall response rate and a 17% complete response rate [33][36] - Expected to enter a global study comparing it with standard care [35] Financial Overview - **Debt Reduction**: Successfully reduced debt to approximately $38.7 million annually after divesting $800 million worth of assets [7][42] - **Cash Position**: Ended Q1 2025 with $82 million in cash, bolstered by a $250 million increase post-divestiture [42][44] - **Cost Management**: Plans to reduce workforce from 225 to about 50 employees, yielding $25 million in savings [42] Strategic Partnerships and Market Opportunities - **Partnerships**: Actively seeking partners for ex-US licensing of pipeline assets [40][41] - **Market Potential**: Combined market opportunity for pipeline assets exceeds $15 billion [6][40] Additional Insights - **Mechanistic Differentiation**: Lactorsi's unique binding mechanism allows for internalization of the PD-1 receptor, enhancing T cell signaling, particularly in low PD-L1 states [9][10][43] - **Clinical Development**: Robust clinical programs with expected results in 2026, focusing on large indications with multibillion-dollar market potential [43][44] - **Regulatory Engagement**: Positive alignment with the FDA regarding the development approach for CHS-114 and Casdozo ketog [28][41] This summary encapsulates the critical points discussed during the conference call, highlighting the strategic direction, product pipeline, financial health, and market opportunities for Coherus BioSciences.

REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc., announced its name change today to better align with its exclusive focus on proprietary innovative immuno-oncology medicines. “The field of cancer immunotherapy has been reinvigorated by the promise and power of combination therapies. Coherus Oncology has the expertise and pipeline to become a significant play ...

Coherus BioSciences (CHRS) FY Conference Summary Company Overview - Coherus BioSciences has transitioned into an innovative oncology company, divesting its biosimilar assets, including Lucentis, Yosemir, and UDENYCA, generating approximately $800 million in total from these divestitures [3][4] - The company has paid off $480 million in long-term debt and added $250 million to its balance sheet [3] Key Developments Loktorzi - Loktorzi is a central asset in Coherus' strategy, with ongoing pivotal trials for additional indications [4][5] - The launch for nasopharyngeal carcinoma (NPC) showed good growth in Q4, but Q1 was flat due to supply interruptions and sales team distractions [10][11] - The focus is on increasing the breadth of physician prescriptions, depth of market penetration, and ensuring patient duration on the product [12][13] Partnerships and Clinical Studies - Coherus announced a partnership for combination studies with STC 15 from Storm Therapeutics, targeting RNA methyltransferase activity, which has shown promise in solid tumors [16][17] - The goal is to drive label expansion for Torapalumab, a next-generation PD-1 inhibitor, through these partnerships [20][21] CHS 1 114 (Treg Depleter) - CHS 1 114 targets CCR8 to selectively deplete tumor-resident Tregs, showing promising early clinical data with significant Treg depletion and CD8 T cell infiltration [23][25][26] - The combination with Torapalumab in late-line head and neck cancer patients has shown early signs of activity, with ongoing studies to evaluate its efficacy further [27][28] Casdozoketug - Casdozoketug is an IL-27 antagonist showing promising results in liver cancer, with a 17% complete response rate in early studies, which is significantly higher than reported rates in phase three studies [41][42] - The company is planning to progress with studies in both liver and lung cancers, with data expected next year [44][46] Financial and Strategic Outlook - Coherus is focused on execution and leveraging its strong track record in development, regulatory affairs, and commercial success [48][49] - The company anticipates promising results from ongoing clinical trials and partnerships, positioning itself for growth in the oncology market [8][49] Additional Insights - The company is actively exploring other tumor types for CHS 1 114, indicating a broadening of its clinical focus [29] - The strategic emphasis on enhancing the commercial story and execution capabilities is expected to drive future success [48][49]

– First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor –REDWOOD CITY, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), today announced a clinical collaboration with STORM Therapeutics, Ltd. (“STORM”) to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor, in a Phase 1b/2 study for the treatment of non-small ...

Financial Data and Key Metrics Changes - The company has transitioned from a biosimilars focus to an innovative immuno-oncology (IO) company, indicating a significant strategic shift [1] - The launch of Lactorsi as a preferred therapy in NCCN guidelines is a notable development, with the team reportedly hitting their stride in Q2 after overcoming earlier disruptions [33] Business Line Data and Key Metrics Changes - The company presented encouraging data for its CCRA antibody, CHS 114, showing a partial response in a patient with advanced refractory disease, highlighting the potential of targeted therapies [2][5] - The combination of CHS 114 with toripalumab has shown marked depletion of T regulatory cells, leading to significant immune cell infiltration, which is a positive indicator for its efficacy [10][11] Market Data and Key Metrics Changes - The company is aware of the looming loss of exclusivity (LOE) for Keytruda in 2028 and is strategically positioning Lactorsi to differentiate itself in the market [15][16] - The competitive landscape is evolving, with the company focusing on novel mechanisms and combinations that could provide advantages over existing PD-1 therapies [17][29] Company Strategy and Development Direction - The company aims to develop both CHS 114 and casdosakitug in combination with toripalumab, seeking to maximize the potential of its pipeline [17][24] - The strategy includes forming partnerships that focus on novel mechanisms of action while maintaining a capital-efficient approach [24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing clinical data flow and the potential for upcoming collaborations, particularly in liver cancer, head and neck, and lung cancer [22][24] - The company is excited about the differentiated mechanism of action of Lactorsi, which has shown activity in PD-L1 low patients, setting it apart from competitors [28][30] Other Important Information - The company has divested from its biosimilar business to focus on innovative oncology, which is seen as a space with greater potential for value creation [40][41] - The safety profile of castosakitug has been well tolerated, with promising early results in lung and liver cancers, indicating a strong potential for future studies [36][38] Q&A Session Summary Question: What was encouraging about the data for the CCRA antibody? - The data showed a partial response in a patient with advanced refractory disease, which is significant given the patient's history of treatment failures [2] Question: How does the company view the competition with Keytruda? - The company is aware of the LOE for Keytruda and believes that their differentiated therapies will maintain a competitive edge despite the upcoming biosimilars [15][16] Question: What is the strategy for partnerships moving forward? - The company is focusing on collaborations that will yield interesting clinical data and is prioritizing partnerships that involve novel mechanisms of action [24][22]

Coherus BioSciences (CHRS) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -12.90%. A quarter ago, it was expected that this drug developer would post a loss of $0.23 per share when it actually produced a loss of $0.28, delivering a surprise of -21.74%.Over the last four quarters, the company ...

Coherus BioSciences (CHRS) Q1 2025 Earnings Call May 12, 2025 05:00 PM ET Company Participants Jodi Sievers - Vice President of Investor Relations & Corporate CommunicationsDennis Lanfear - Chairman, President & CEOTheresa Lavallee - Chief Scientific & Development OfficerRosh Dias - Chief Medical OfficerSameer Goregaoker - EVP - CommercialBryan McMichael - CFOKripa Devarakonda - Vice President - Biotechnology Equity ResearchMichael Nedelcovych - Director - Equity Research Conference Call Participants Brian ...

Financial Data and Key Metrics Changes - The company reported a revenue of $7.3 million for Q1 2025, which remained flat due to a seasonal inventory drawdown despite a 15% growth in patient demand [38][39] - Cost of Goods Sold (COGS) from continuing operations increased to $2.7 million from $1.4 million in Q1 last year, attributed to increased sales of Lactorsi [47] - Research and Development (R&D) expenses decreased by 14% to $24.4 million, reflecting savings from reduced co-development with Junshi [48] - Selling, General and Administrative (SG&A) expenses decreased by 35% to $26 million, primarily due to lower headcount and non-recurring charges from the previous year [48] Business Line Data and Key Metrics Changes - The company is now focused solely on its innovative oncology business, with Lactorsi being the only FDA-approved treatment for metastatic recurrent locally advanced nasopharyngeal carcinoma [6][8] - Lactorsi is projected to grow to approximately $150 million to $200 million annually over the next three years, providing non-dilutive funding for the development pipeline [8][9] - The commercial team has successfully remapped territories and updated customer assignments post-UDENYCA divestiture, with a focus on driving growth in appropriate NPC patients [37][38] Market Data and Key Metrics Changes - The company noted a significant number of patients still receiving non-preferred chemotherapy and off-label immuno-oncology treatments, indicating a market opportunity for Lactorsi [38] - The NCCN guidelines now place Lactorsi in a preferred position for recurrent and metastatic patients, which the company is actively promoting to healthcare providers [38][41] Company Strategy and Development Direction - The company’s strategy is anchored around three core pillars: Lactorsi, CHS-114 (a selective CCR8 cytolytic antibody), and casdosoketogue (an anti-IL-27 antibody) [6][12][13] - The company aims to expand Lactorsi's indications through partnerships and combination therapies, enhancing its market presence and revenue potential [10][11] - The focus on innovative oncology is expected to drive long-term value for shareholders while addressing significant unmet medical needs in cancer treatment [50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company’s ability to navigate recent FDA changes and emphasized the importance of strong development expertise in adapting to regulatory environments [52][56] - The company anticipates that the restructuring of the sales force will lead to accelerated growth in Q2 and beyond, despite transitional challenges faced in Q1 [60][68] - Management highlighted the promising clinical data for CHS-114 and its potential to address PD-1 resistance, which could significantly impact treatment paradigms in oncology [30][36] Other Important Information - The company completed the divestiture of UDENYCA, receiving $483 million in upfront cash and repurchasing $170 million of convertible notes [43][44] - The net cash from these transactions is expected to provide substantial liquidity for ongoing operations and development initiatives [44] Q&A Session Summary Question: What needs to happen for a significant inflection point for Lactorsi? - Management noted that increased awareness among providers and ongoing clinical trials will be crucial for driving adoption and market share [51][56] Question: Can you clarify patient demand for Lactorsi? - Demand is defined as actual patient growth, with a 15% increase in end-user demand reported, indicating strong physician engagement [65][66] Question: Will the Salesforce restructure impact future projections? - The impact of the restructure was primarily felt in Q1, but management expects Q2 and Q3 to be growth periods for the brand [68] Question: Are there any competitor molecules that have proven the efficacy of CCR8 targeting? - Management indicated that while selectivity is a challenge, there are emerging data points suggesting the relevance of CCR8 targeting in certain tumor types [72][75]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 Coherus BioSciences, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Inco ...

Exhibit 99.1 Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update – Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L HNSCC ongoing – – Enrollment ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1 ...